| Literature DB >> 31251821 |
Ifeoma Mary Eche1, Pansy Elsamadisi1, Nicole Wex1, Mark C Wyers2, Gabriel A Brat3, Katherine Cunningham1, Kenneth A Bauer4.
Abstract
The authors describe a case of unfractionated heparin (UFH) unresponsiveness in the operating room secondary to reversal of rivaroxaban with coagulation factor Xa (recombinant) inactivated-zhzo (andexanet alfa). A 70-year-old man with a known 4.5- to 5.0-cm abdominal aortic aneurysm and atrial fibrillation managed with rivaroxaban presented with severe right-sided flank pain radiating to the left side of his abdomen. Computed tomography-angiography on arrival demonstrated a left retroperitoneal hematoma and a suspected ruptured abdominal aortic aneurysm. He received andexanet alfa to reverse rivaroxaban prior to an emergent endovascular aneurysm repair. During surgery, he received a total of 14,000 units (167 units/kg) of UFH with minimal changes in activated clotting time (132-144 sec; baseline 135 sec [reference range 74-137 sec]). This case highlights the potential complications of using UFH anticoagulation following reversal of factor Xa inhibitors with andexanet alfa and underscores the importance of peri-procedural anticoagulation planning. For patients who require intra-operative anticoagulation, providers should consider anticoagulation reversal with prothrombin complex concentrate instead of andexanet alfa or administration of a parenteral direct thrombin inhibitor, such as argatroban or bivalirudin during the surgical procedure.Entities:
Keywords: abdominal aortic aneurysm; andexanet alfa; direct oral anticoagulants; endovascular aneurysm repair; endovascular repair; factor Xa reversal; rivaroxaban; unfractionated heparin unresponsiveness
Mesh:
Substances:
Year: 2019 PMID: 31251821 DOI: 10.1002/phar.2306
Source DB: PubMed Journal: Pharmacotherapy ISSN: 0277-0008 Impact factor: 4.705